CTLA4 and non-small cell lung carcinoma: The phase III randomised clinical trial CheckMate 9LA evaluated the combination of nivolumab (a PD‐1 inhibitor) and ipilimumab (a CTLA‐4 inhibitor) with chemotherapy in patients with advanced NSCLC, revealing that this combination therapy effectively improves immune evasion in the tumour microenvironment, significantly prolonging patient survival.237